Nuclear Magnetic Resonance Fragment-Based Identification of Novel FKBP12 Inhibitors
作者:John L. Stebbins、Ziming Zhang、Jinhua Chen、Bainan Wu、Aras Emdadi、Megan E. Williams、John Cashman、Maurizio Pellecchia
DOI:10.1021/jm0707424
日期:2007.12.27
Peptidyl-prolyl cis-trans isomerases are a group of cytosolic enzymes initially characterized by their ability to catalyze the cis-trans isomerization of peptidyl-prolyl bonds. This represents a significant event for protein folding because cis-proline introduces critical bends within the protein conformation. FK506-binding proteins (FKBPs) represent one of the three families of enzymes sharing peptidyl-prolyl
肽基-脯氨酰顺反异构酶是一组胞质酶,其最初特征在于它们催化肽基-脯氨酰键的顺反异构化的能力。这代表了蛋白质折叠的重要事件,因为顺式脯氨酸在蛋白质构象内引入了关键的弯曲。FK506结合蛋白(FKBPs)代表共享肽基-脯氨酰顺反异构酶活性的三个酶家族之一。FKBP12抑制剂尤其在体内和体外均具有有效的神经营养特性。在这里,我们描述了一种基于片段的无偏核磁共振药物发现方法,用于识别针对FKBP12的新型化学抑制剂。与FK506相比,本文开发的基于片段的FKBP12抑制剂作为候选药物具有明显的优势。